Carregant...
Fitxers
Tipus de document
ArticleData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178818
Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Only a fraction of cancer patients benefits from immune checkpoint inhibitors. This may be partly due to the dense extracellular matrix (ECM) that forms a barrier for T cells. Comparing five preclinical mouse tumor models with heterogeneous tumor microenvironments, we aimed to relate the rate of tumor stiffening with the remodeling of ECM architecture and to determine how these features affect intratumoral T cell migration. An ECM-targeted strategy, based on the inhibition of lysyl oxidase, was used. In vivo stiffness measurements were found to be strongly correlated with tumor growth and ECM crosslinking but negatively correlated with T cell migration. Interfering with collagen stabilization reduces ECM content and tumor stiffness leading to improved T cell migration and increased efficacy of anti-PD-1 blockade. This study highlights the rationale of mechanical characterizations in solid tumors to understand resistance to immunotherapy and of combining treatment strategies targeting the ECM with anti-PD-1 therapy.
Matèries
Matèries (anglès)
Citació
Citació
NICOLAS BOLUDA, Alba, VAQUERO, Javier, VIMEUX, Lene, GUILBERT, Thomas, BARRIN, Sarah, KANTARI MIMOUN, Chahrazade, PONZO, Matteo, RENAULT, Gilles, DEPTULA, Piotr, POGODA, Katarzyna, BUCKI, Robert, CASCONE, Ilaria, COURTY, José, FOUASSIER, Laura, GAZEAU, Florence, DONNADIEU, Emmanuel. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. _eLife_. 2021. Vol. 10, núm. e58688. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/178818]